Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01749046
Other study ID # 11-MPP02EPI
Secondary ID 11-???02??I
Status Completed
Phase Phase 3
First received December 11, 2012
Last updated May 10, 2017
Start date March 2012
Est. completion date December 2013

Study information

Verified date May 2017
Source Valexfarm
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is effictive and safe in patients with epilepsy with partial seizures


Description:

Phase III


Recruitment information / eligibility

Status Completed
Enrollment 224
Est. completion date December 2013
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Man or woman, aged from 18 to 65

- Diagnosis of epilepsy with simple and/or complex partial seizures both with or without secondary generalization based on the ILAE classification

- Results of at least one prior electroencephalogram (EEG) and magnetic resonance imaging (MRI)/computerized tomography scan no more than 5 years should confirm the diagnostic of partial seizures

- If seizures are simple partial ones, only patients with motor signs must be enrolled

- The onset date of partial seizures according to patient's report must be at least 2 years

- The patient must report an average of at least 8 partial seizures per 56 days prior to the baseline visit

- The patient must not have seizure-free period longer than 21 days during the 8 weeks prior to the baseline visit (i.e between V1 and V2)

- Patients must have been treated with at least 2 different AEDs within the last 2 years prior to the screening visit

- The patient is capable and would like to respect all protocol requirements, include to be available for the doctor's calls and doctor's appointments at any time, follow through all protocol procedures

- The patient agrees to self - report each seizure he has experienced between 2 visits, accurately and thoroughly, in a diary he'll be provided with

Exclusion Criteria:

- Patients suffering from non-epileptic seizures

- Patients having seizures that can't be counted due to clustering.

- History of primary generalized seizures

- History of status epilepticus within 12 months prior to the screening visit

- The patient has received not permitted concomitant medications

- The patient has a progressive structural lesion in the CNS, or a progressive encephalopathy

- The patient is pregnant (or planning to become pregnant during the study) or is a lactating woman

- The patient has used Remegal previously or participated in a clinical study within 24 weeks prior to the screening visit

- The patient has experienced of any somatic disorders or psychiatric diseases and conditions which, in the opinion of the investigator, lead to health worsening or influence on the patient ability to participate in the actual clinical study

- Vulnerable patients and individuals of majority age who are subject to legal protection or unable to express their consent

- The patient has a history of chronic alcohol consumption or drug abuse within 2 years prior to the screening visit

- The patient has a known history of a severe anaphylactic reaction or severe changes in blood tests

- ALT, AST, alkaline phosphatise, total bilirubin or serum creatinine level = 2 times the upper limit of normal ranges

- Clinically important abnormalities on physical examination, vital signs, ECG or laboratory test results per-formed/obtained at the screening visit that may interfere with patient's safety, compliance, or study evaluations, ac-cording to the Investigator's opinion

- The patient has a clinically significant disease, surgical condition or recent chronic consumption of non-AED medications (within 4 weeks prior to the screening visit) that might be reasonably expected to interfere with drug absorption, distribution, metabolism, excretion

- QTc interval on the ECG performed at the screening visit above 500 ms

- Diseases or concomitant medications that may prolong QTc interval

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Remegal
Remegal 1500 mg for 12 weeks

Locations

Country Name City State
Russian Federation Sverdlovsk region neuropsychiatric clinic Ekaterinburg
Russian Federation Region psychiatric clinic Kemerovo
Russian Federation Moscow regional psychiatric hospital Moscow
Russian Federation State Medical University Novosibirsk
Russian Federation State psychiatric hospital ?6 Saint-Petersburg
Russian Federation State Medical University Samara
Russian Federation Republican psychiatric dispensary Saransk
Russian Federation State Medical Academy Smolensk
Russian Federation Medical unit of disel equipment Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
Valexfarm

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seizure Frequency Reduction The assessment of efficacy will be based on the reduction of total partial seizure frequency reported in the patient's diary during the Treatment phase. 12 weeks
Secondary Number of Seizure's-Free Days Number seizure's-free days during the Maintenance phase 12 weeks
Secondary CGI Clinical Global Impression of change (CGI) at the end of Titration and Maintenance phases 12 weeks
Secondary PGI Patients' Global Impression of change (PGI) at the end of the Titration and Maintenance phases 12 weeks
Secondary QOLIE Assessment of Quality of Life Instrument in Epilepsy (QOLIE) at the Baseline Visit and at the end of Maintenance Phase 14 weeks
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A